Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted first-line intensification with R-ICE and Z-BEAM/ASCT in high-risk CD20-positive DLBCL
ACTRN12609001077257Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 7 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started Jul 2009; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12609001077257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001077257.